BioFire, Focus, IQuum Share $23.1M to Develop Platform, Assays for Biological Warfare Agent Detection | GenomeWeb

NEW YORK (GenomeWeb News) – The Department of Defense has awarded more than $23 million to three firms for the development of a platform and assays to detect biological warfare agents, the agency announced last week.

BioFire Diagnostics, Focus Diagnostics, and IQuum will share the $23.1 million cost-plus-fixed-fee multiple award task order contract being awarded through the US Army to develop a US Food and Drug Administration-cleared diagnostic platform and related FDA-cleared biological warfare agent in vitro diagnostic assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.